

# **Inhaled Corticosteroids and Its Effect on Growth and Puberty of Asthmatic Children**

*Thesis*

**Submitted for partial fulfillment  
of Master degree of Pediatric**

*By*

**Nasr-Eldin Abd-El-Monam Sayed Ahmed**

*M.B., B.Ch, Al-Azhar University (2002)*

*Supervised by:*

**Prof. Zeinab Awad El-Sayed**

Prof. of Pediatrics

Faculty of Medicine

Ain-Shams University

**Dr. Rasha Tarif Mohammed Hamza**

Lecturer of Pediatrics

Faculty of Medicine

Ain-Shams University

**Dr. Nermine Helmy Mahmoud**

Lecturer of Clinical Pathology

Faculty of Medicine

Ain-Shams University

*Faculty of Medicine  
Ain- Shams University  
2009*

## **ACKNOWLEDGMENT**

*At first and foremost thanks to “ALLAH” who granted me the power to finish this work.*

*I wish to express my deepest thanks and gratitude to **Professor. Zeinab Awad El-Sayed**, professor of Pediatrics, Faculty of medicine, Ain Shams University, who gave me the honor of working under her supervision and who was kind enough to offer me much of her valuable time and sincere advice.*

*My utmost thanks and appreciation are duo to **Dr. Rasha Tarif Mohammed Hamza**, Lecturer of Pediatrics, Faculty of medicine, Ain Shams University, for her valuable remarks and generous support throughout this whole work. My deep gratitude goes to her faithful and meticulous supervision during every step of this work.*

*I would like to express my deep appreciation to, **Dr. Nermin Helmy Mahmoud**, Lecturer of Clinical Pathology, Faculty of medicine, Ain Shams University , for her great cooperation and his active skillful participation throughout the practical part.*

*Finally, many thanks to my patients and their parents who have made this work possible.*

# List of Abbreviations

ADAM33	A desintegrin and Metalloproteinase 33
AHR	Airway hyperresponsiveness
APC's	Antigen presenting cells.
ACTH	Adrenocorticotrophic hormone.
ADH	Antidiuretic hormone.
AMSH	Alpha-melanocyte stimulating hormone.
Pmdi	A pressurized metered-dose inhaler.
ALS	Acid-labile subunit.
ASM	Airway smooth muscle cell
BA	Bone age.
BMI	Body mass index.
BHR	Bronchial hyperresponsiveness
BAL	Bronchoalveolar lavage.
CNS	Central nervous system.
CD8	Cluster of differentiation type 8.
C3a, C5a	Complement proteins.
COAP	Anteroposterior diameter of the corpus.
CEAP	Anteroposterior diameter of the cervix.
CA	Chronologic age.
COPD	Chronic obstructive pulmonary diseases
CysLTs	Cysteinyl leukotrienes
DPI	Dry powder inhaler.
DCs	Dendritic cells
ECP	Eosinophilic cationic protein.
ETS	Environmental tobacco smoke
FSH	Follicular stimulating hormone.
FDA	The food and drug administration
FEV <sub>1</sub>	Forced expiratory volume in 1 second
FLAP	5-lipoxygenase-activating protein. FVC: forced vital capacity.
GERD	Gastroesophageal reflux
GM-CSF	Granulocyte-macrophage colony-stimulating factor.
GCs	Glucocorticoids
GH	Growth hormone.
GHRH	Growth hormone-releasing hormone.
GHBP	Growth hormone binding protein.
GH-IGF	Growth hormone -insulin-like growth factor axis.
GHRP	Growth hormone releasing peptides.
GHR	Growth hormone receptor.

## List of abbreviations (Cont.)

GnRH	Gonadotropine releasing hormone.
HPA	Hypothalamic pituitary axis
HLA	Human leukocyte antigen
HDM	House Dust Mite extract
IL	Interleukin.
IgE	Immunoglobulin-E
IFN	Interferon.
ICS	Inhaled corticosteroids.
IOS	Impulse oscillometry.
IGF-1	Insulin like growth factor-1.
IGFBP	IGF-binding proteins.
LH	Lutenizing hormone.
LABAs	Long-acting beta-2 agonists
LHRH	Lutenizing hormone releasing hormone.
LTC <sub>4</sub>	Leukotriene C <sub>4</sub> .
LTB <sub>4</sub>	Leukotrienes B <sub>4</sub> .
LOX5	5-Lipoxygenase
LTRAs	Leukotriene receptor antagonists
LT	Leukotriene modifiers
LTRAs	Leukotriene receptor antagonists
MBP	Major basic protein.
M rIFN	Nebulized recombinant interferon
MCs	Mast cells
CP-1	Monocytic chemoattractant protein.
NKA	Neurokinin A
NANC	Nonadrenergic, noncholinergic.
O <sub>3</sub>	Ozone
PDE4	Phosphodiesterase inhibitors
PEFR	Peak expiratory flow rate
PHF11	Plant Homeodomain Zinc Finger Protein 11
PAF	Platelet Activating Factor.
PEF	Peak Expiratory Flow
PDGF	Platelet-derived growth factor.
PM	Particulate matters.
RSV	Respiratory Syncytial Virus.
RANTES	Regulation upon activation normal T cell expressed and secreted.
RAST	Radioallergosorbent test.

## List of abbreviations (Cont.)

Rrs	Total respiratory resistance
SS	Somatostatin secretion.
SDS	Standard deviation score.
SNPs	Single nucleotide polymorphisms
SIT	Sublingal immunotherapy
SP	Substance P
SMR	Sexual Maturity Ratings.
SLIT	Sublingual immunotherapy
TGF	Transforming growth factor.
Th	T-helper cells
TNF	Tumor necrosis factor
TXA2	Thromboxane A2.
VC	Vital capacity.

## List of Tables

Tab. No.	Title	Page No.
<b>(In Review)</b>		
Table (1):	Factors influencing the development and expression of asthma.....	5
Table (2):	Triggers of Asthma. ....	12
Table (3):	Inflammatory cells involved in asthma....	15
Table (4):	T-helper Cell Subtypes Classified by Cytokine Production .....	17
Table (5):	Classification of asthma severity by clinical features before treatment.....	27
Table (6):	Differential diagnostic possibilities for asthma.....	28
Table (7):	Levels of Asthma Control.....	31
Table (8):	Estimated Equipotent Doses of Inhaled Glucocorticosteroids for Children.....	37
Table (9):	Normal growth rate. ....	48
Table (10):	Causes of short stature.....	59
Table (11):	Sequence of events for adolescent girls.....	62

## **List of Tables (cont.)**

Tab. No.	Title	Page No.
Table (12):	SMR pubic hair stages: Mean chronologic age (CA) and bone age (BA) in males and females (in years).....	64
Table (13):	SMR Female Breast Stages: Mean chronologic age (CA) and bone age (BA) in females (in years).....	64
Table (14):	SMR Male Genital Stages. Mean chronological age (CA) and bone age (BA) in males (in years).....	65
Table (15):	Hormones affecting puberty.....	66
Table (16):	Ovarian volume in relation to age (mean $\pm$ SD)....	75
Table (17):	Uterine volume in relation to age.....	75

## **(In Results)**

Table (18):	Descriptive clinical, laboratory and demographic data of patients.....	95
Table (19):	Distribution of dose and duration of steroids among patients.....	96
Table (20):	Comparison of age, height and weight among patients and controls.....	97
Table (21):	Comparison of SDS of height for age and SDS of weight for height among patients and controls.....	98

## List of Tables (cont.)

Tab. No.	Title	Page No.
	Table (22): Comparison of bone age and its SDS among patients and controls.....	99
	Table (23): Relationship between each of the doses and duration of steroid therapy and Tanner staging among patients aged $\geq 11$ years in girls and $\geq 11.5$ years in boys.....	101
	Table (24): Comparison of each of bone age, SDS of bone age among patients aged $\geq 11$ years according to Tanner stage.....	102
	Table (25): Comparison of each of uterine length, SDS of uterine length, right ovarian volume, SDS of right ovarian volume among patients aged $\geq 11$ years according to Tanner stage.....	103
	Table (26): Relation between dose of steroid therapy and each of age, height, weight, PAH among patients group.....	104
	Table (27): Comparison of height, weight, SDS of weight for height in steroid therapy at dose $<400$ and at duration $< 1$ year among patient and control.....	105



## List of Tables (cont.)

Tab. No.	Title	Page No.
	Table (28): Relation between dose of steroids and each of SDS of height for age, SDS of weight for height, bone age and its SDS in patients group.....	106
	Table (29): Relation between duration of steroid therapy and each of age, height, weight, PAH among patients group.....	107
	Table (30): Relation between duration of steroid therapy and each of SDS of height for age, SDS of weight for height, bone age and its SDS among patients group.....	107
	Table (31): Relation between dose of steroid therapy and each of uterine length and right ovarian volume among patients group.....	108
	Table (32): Relation between dose of steroids and each of SDS of uterine length, SDS of right ovarian volume in patients group.....	109
	Table (33): Relation between dose of steroids and each of basal FSH and FSH after decapeptyl stimulation in patients group.....	109
	Table (34): Comparison of each of basal LH and LH after decapeptyl stimulation in patients group according to dose of steroids.....	110

## List of Tables (cont.)

Tab. No.	Title	Page No.
	Table (35): Percentage of asthmatic children on steroid therapy who exhibit delayed puberty based on low FSH and LH levels.....	111
	Table (36): Relation between each of doses and duration of steroids therapy in asthmatic children with delayed puberty based on low FSH and LH levels.....	111
	Table (37): Relation between duration of steroid therapy and each of uterine length and right ovarian volume among patients group.....	112
	Table (38): Relation between duration of steroid therapy and each of SDS of uterine. Length and SDS of right ovarian volume among patients group.....	112
	Table (39): Comparison of each of basal FSH and FSH after decapeptyl stimulation in patients group according to duration of steroid therapy. ....	113
	Table (40): Comparison of each of basal LH and LH after decapeptyl stimulation in patients group according to duration of steroid therapy.....	113
	Table (41): The matrix correlation between FSH and LH basal and after decapeptyl with uterine length, SDS of uterine length, right ovarian volume, SDS of right ovarian volume and bone age.....	114

## List of Figures

Fig. No.	Title	Page No.
<b><u>(In Review)</u></b>		
Fig. (1):	Differentiation of Th1 and Th2 cells by their cytokine profiles.....	18
Fig. (2):	Effects of restrictive and intrathoracic obstruction on the divisions of total lung capacity.....	24
Fig.(3):	Approach for managing asthma in children.....	33
Fig.(4):	Leukotriene modulators.....	39
Fig. (5):	Egyptian Growth Charts, (Girls 2 – 21 years),.....	49
Fig. (6):	Egyptian Growth Charts, (Boys 2 – 21 years),.....	50
Fig. (7):	Hormonal regulation of growth hormone secretion .....	54
Fig.(8):	Schematic representation of the GH-IGF axis.....	56
Fig. (9):	Diagrammatic representation of the neuroendocrine- ovarian axise involved in normal pubertal development....	69
Fig. (10):	Microcystic follicles. ....	72

## List of Figures (cont.)

Fig. No.	Title	Page No.
Fig. (11):	Longitudinal section of the right ovary in a 15 years old.....	73
Fig. (12):	Prepubertal uterus.....	74
Fig. (13):	Ovarian Volume.....	76
Fig. (14):	Uterine Volume.....	77
Fig. (15):	Distribution of ICS. Systemic bioavailability of each drug.....	68
<b><u>(In Results)</u></b>		
Fig.(16):	Sex distribution among patients and controls..	96
Fig. (17):	Comparison of height among patients and controls.	97
Fig (18):	Comparison of weight among patients and controls.	98
Fig.(19):	Comparison of SDS of height for age and weight for height among patients and controls.....	99
Fig.(20):	Comparison of SDS of height for age and weight for height among patients and controls.....	100
Fig. (21):	Comparison of Tanner staging among patients and controls girls aged $\geq 11$ years and boy's $\geq 11.5$ years..	100
.		

## List of Figures (cont.)

Fig. No.	Title	Page No.
Fig. (22):	Uterine length and right ovarian volume according to Tanner stage among girls aged $\geq 11$ years in the patients	
Group.....		102
Fig.(23):	Comparison of each of bone age, SDS of bone age among patients aged $\geq 11$ years according to Tanner stage.....	103
Fig.(24):	Comparison of each of uterine length, SDS of uterine length and SDS of right ovarian volume among patients aged $\geq 11$ years according to Tanner stage.....	104
Fig.(25):	Relation between each of dose and duration of steroid therapy and height among patient group.....	105
Fig.(26):	Relation between dose of steroids and each of SDS of height for age, SDS of weight for height, bone age, SDS of BA, SDS of uterine length, SDS of right ovarian volume in patients group.....	106
Fig.(27):	Relation between duration of steroid therapy and each of SDS of height for age, SDS of weight for height, bone age and its SDS among patients group.....	108
Fig.(28):	Comparison of each of FSH and LH basal and after decapeptyl stimulation in patients group according to dose of steroids.....	110

## **List of Figures (cont.)**

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
Fig.(29):	Comparison of each of FSH and LH basal and after decapeptyl stimulation in patients group according to duration of steroid therapy.....	114
Fig.(30):	Correlation between basal FSH and SDS of uterine length.....	115
Fig.(31):	Correlation between basal FSH and right ovarian volume.....	116
Fig.(32):	Correlation between FSH after decapeptyl and uterine length.....	116
Fig.(33):	Correlation between FSH after decapeptyl and SDS of uterine length.....	117
Fig.(34):	Correlation between FSH after decapeptyl stimulation and right ovarian volume.....	117
Fig.(35):	Correlation between basal LH and SDS of uterine length.....	118
Fig.(36):	Correlation between LH after decapeptyl stimulation and uterine length.....	118
Fig.(37):	Correlation between LH after decapeptyl stimulation and SDS of uterine length.....	119

## **List of Figures (cont.)**

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
Fig.(38):	Correlation between LH after decapeptyl stimulation and right ovarian volume.....	119
Fig.(39):	Correlation between LH after decapeptyl stimulation and SDS right ovarian volume.....	120